High-resolution structure reveals how LSD binds to and activates the canonical mind-altering receptor.
For humans, drug doses are based largely on body weight. But in animals, differences in brain and body chemistry make the calculations far more complicated.
The “psychedelic drug” label appears to define a clear-cut category. However, there are lesser-known research chemicals that depict more diffuse boundaries in this classification.
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
The primary active compound in this plant is more potent than LSD.
Using psychedelics to treat chronic pain is understudied yet full of potential.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.